Awareness: On Drug Labels, Vital Facts May Be Missing
Submitted by admin on October 30, 2009 – 9:48 amNo Comment | 27 views
Federal officials who approve new drugs review an enormous amount of data about their effectiveness and harmful side effects, but critical information often fails to reach the doctors who prescribe them, two Dartmouth Medical School researchers write in the Oct. 29 issue of The New England Journal of Medicine.
In the case of the sleeping pill Rozerem (ramelteon), for example, one review document from the Food and Drug Administration states that the drug made “no significant difference in time to fall asleep” and that patients “do not seem to recognize any benefit from treatment.”
Read the full article on the New York Times website.
Related posts:
- Experts: Key drug facts often left off FDA labels
- Document Details Forest Labs’ Plan to Promote Costly Drug Lexapro
- Much-criticised FDA medical device approvals get external review
- FDA fails to follow up on unproven drugs
- Beleagured Food and Drug Administration Reveals It Succumbed to a Push by “Paid-For Lawmakers”
